Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Free Cash Flow of -$46.3 million for Q1 2026, up 2.82% on a QoQ basis from -$47.7 million in Q4 2025, and up 8.0% year-over-year from -$42.9 million in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Free Cash Flow (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$46.3 million for Q1 2026.
- Quarterly Free Cash Flow rose 8.0% year-over-year to -$46.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$174.7 million (up 48.09% YoY) and the FY2025 annual result came in at -$178.7 million, up 53.23% from the prior year.
- Free Cash Flow was -$46.3 million for Q1 2026 at Ginkgo Bioworks Holdings, up from -$47.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$17.7 million in Q1 2022 and bottomed at -$146.8 million in Q4 2022.
- A 5-year average of -$73.4 million and a median of -$78.5 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow jumped 74.76% — and 2023, when it slumped 522.11%.
- Ginkgo Bioworks Holdings' Free Cash Flow stood at -$146.8 million in 2022, then surged by 34.67% to -$95.9 million in 2023, then retreated by 9.26% to -$104.8 million in 2024, then surged by 54.49% to -$47.7 million in 2025, then advanced by 2.82% to -$46.3 million in 2026.
- Business Quant data shows DNA's Free Cash Flow at -$46.3 million in Q1 2026, -$47.7 million in Q4 2025, and -$39.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -46.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.34 Mn |
| Mar 31, 2026 | -46.34 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Dec 31, 2025 | -47.68 Mn |
| Sep 30, 2025 | -39.14 Mn |
| Sep 30, 2025 | -39.14 Mn |
| Jun 30, 2025 | -41.53 Mn |
| Jun 30, 2025 | -41.53 Mn |
| Mar 31, 2025 | -50.37 Mn |
| Mar 31, 2025 | -50.37 Mn |
| Dec 31, 2024 | -104.78 Mn |
| Dec 31, 2024 | -104.78 Mn |
| Sep 30, 2024 | -102.86 Mn |
| Sep 30, 2024 | -102.86 Mn |
| Jun 30, 2024 | -78.51 Mn |
| Jun 30, 2024 | -78.51 Mn |
| Mar 31, 2024 | -95.97 Mn |
| Mar 31, 2024 | -95.97 Mn |
| Dec 31, 2023 | -95.90 Mn |
| Dec 31, 2023 | -95.90 Mn |